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97Introduction
The use of a mechanistic ‘Adverse Outcome Pathway’ (AOP) ap-
proach has been highlighted in recent years as having the poten-
tial to improve chemical and drug safety assessment. AOPs
support an understanding of how perturbation of normal biology
can lead to an adverse outcome, by linking a molecular initiating
event (MIE) for a drug or other chemical to an apical endpoint
and subsequent organism/population effects, through a transpar-
ent, scientifically proven causal chain of events (Fig. 1).
The AOP concept is not new and has been described to varying
extents under a number of guises such as ‘toxicity pathways’, ‘mode
of action’ and ‘mechanism of action’ (NRC, 2007; Wilkinson et al.,
2000; Sonich-Mullin et al., 2001). There is considerable overlap in
these terms and to some degree their definitions converge, with
all terms focused on understanding the underlying biological mech-
anisms and pathways associated with the development of adverse
effects. The critical defining factor of an AOP is that it anchors the
MIE to an adverse outcome, which is of importance within a regula-
tory context (i.e. the identification of adverse effects at an organism
or population level). Therefore, an AOPmust contain an appropriate
level of information regarding the causal key events that link theMIE
and an adverse effect. It is these unique properties whichmean that
AOPs could be of tangible benefit to the development of new strat-
egies for the safety assessment of both drugs and other chemicals.
Despite the fact that pharmaceuticals differ from chemicals encoun-
tered in the workplace and environment in terms of their usage and
exposure, and the need to offset risk against benefit, it is apparent
that AOPs offer important benefits in both areas.
AOPs are being developed to different extents worldwide.
However, there is a continuing debate surrounding what is
understood by the term AOP, and their intended use and applica-
tion. It has been recognized that to realize their widespread use inJ. Appl. Toxicol. 2015; 35: 971–975 Copyright © 2015 The Authors. Journal ofpractice, the adoption of an explicit, consensus-led framework
under which AOPs are developed and applied is crucial. In
addressing this, the Organisation for Economic Co-operation and
Development (OECD) AOP Development Programme (www.oecd.
org/chemicalsafety/testing/adverse-outcome-pathways-molecular-
screening-and-toxicogenomics.htm) has led to the establishmentApplied Toxicology published by John Wiley & Sons Ltd.
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Figure 1. Schematic representation of the Adverse Outcome Pathways (AOP) with reference to examples of different pathways (adapted from an OECD
figure, found at http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-toxicogenomics.htm).
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972of such a framework. AOPs not only have the potential to transform
safety assessment, but in the longer term offer benefits associated
with a reduced reliance on in vivo testing in this area. Furthermore,
moving away from the traditional animal models could drive an in-
crease in the predictivity of toxicity testing. Important in this respect
is an increased focus on consideration of species-relevant biology,
for example through the use of human cell-based systems, and
through the potential address more effectively aspects of inter-
individual variability.
This article explores the opportunities that the development
and implementation of the AOP framework offers the toxicology
community, with a focus on the potential to reduce and replace
the use of animals in regulatory human and environmental safety
assessment, while recognizing the hurdles that must be overcome
in the coming years before these opportunities can be exploited to
their maximum potential.How Will the Application of AOPs Improve the Science and
Practice of Safety Assessment, while Reducing our Reliance on
Animal Tests?
AOPs are essentially a systematic way to organize, integrate and
communicate mechanistic knowledge and information; their
application holds great promise to increase the utilization of non-
animal testmethods that typically providemechanistic information,
to the benefit of the process of safety assessment, providing that in-
formation is used and interpreted prudently. Once developed,
AOPs can be applied in two different ways: (i) to explain an ob-
served adverse outcome in terms of an MIE and key events (a
‘top-down’ approach, which is reliant on in vivo toxicology); or (ii)
to predict the likely adverse outcome after determination of an
MIE and downstream key events (or ‘bottom-up’ approach, which
employs non-animal methods). A targeted focus on applying the
latter would enable a shift in the practice of safety assessment away
from the traditional manner of measuring apical endpoints, to-
wards the use of biological information generated using in silico
and in vitromethods to predict whether a chemical causes specific
perturbations, which we are confident would lead to apical re-
sponses. As AOPs describe the sequence of key events that lead
to adversity at different levels of biological organisation, high
throughput in vitro approaches (such as reporter gene assays that
reflect specific molecular and cellular events) can be utilized to indi-
cate toxic potential. In this way, AOPs could provide a bridge be-
tween non-animal methods and systems toxicology, which could
well improve the discipline of non-animal based safety assessment.
There is also the pragmatic recognition within the toxicologywileyonlinelibrary.com/journal/jat Copyright © 2015 The Authors.
published by John Wcommunity that alternative methods will not replace in vivo
methods on a like-for-like basis, and therefore AOPs will be used
to form part of the scientific basis that informs and directs inte-
grated approaches to testing and assessment (IATA; Patlewicz
et al., 2014).
AOPs also provide the opportunity to extrapolate effects between
species, qualitatively and quantitatively, through the identification
of conserved MIEs, key events and key event relationships. The
science of safety assessment would, therefore, be enhanced if AOPs
could be used to extrapolate experimental outcomes accurately in
populations of organisms in the environment to responses observed
in humans. Furthermore, the categorical demonstration of conserva-
tion across species may decrease the numbers of different species
which must be used in toxicity testing, including higher-order
species such as non-human primates, and would have obvious
benefits in improving the accuracy of ecotoxicological assessments.
It is important to emphasize that accurate and relevant data will be
required for progress towards the development and application of
truly relevant methods. This might include building databases to
share information on cross-species conservation.
The ongoing, iterative nature of the AOP development process
means that gaps in our knowledge and the need for further re-
search will be highlighted. Identification of the key data gaps
could help to drive forward advances in non-animal approaches
to help fill these gaps. There is also the opportunity for AOPs to
drive novel approaches to hazard characterisation, e.g. through
the development of mechanism-based biomarkers. The utility of
AOPs is apparent not only in a regulatory setting – they also have
potential to be used during early screens, to identify compounds/
substances that are likely to be associated with an unwanted ad-
verse effect. There is certainly scope to use the AOPs that are in early
development (i.e. less comprehensively described), in this context.
Such approaches could be used for compound selection or product
prioritisation, and would potentially reduce the amount of later
in vivo testing carried out and reduce the severity of any responses
during such testing. However, for their ultimate application in safety
assessment, the methods used must be capable of providing quan-
tifiable readouts which are informative of the ‘tipping points’ that
propagate the pathways, and we must be confident that the tools
and measures used are appropriate and fit-for-purpose.What is Needed to Realise the 3Rs Benefits of the AOP
Approach?
Although laudable in its intentions, the development of AOPs
themselves is not enough to achieve a shift towards moreJ. Appl. Toxicol. 2015; 35: 971–975Journal of Applied Toxicology
iley & Sons Ltd.
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97mechanistic, animal-free predictions of toxicity. To have genuine
utility and impact on the replacement, refinement and reduction
of animals – the 3Rs – they must be organized and applied under
the auspices of the framework, which has been designed to enable
coherency and to be accessible across the relevant scientific disci-
plines. It provides a systematic and structured way of capturing,
curating and evaluating mechanistic knowledge, to render it prac-
ticably useable by a variety of non-toxicology-expert users. Tools
that shape this framework are now available, including the AOP
Wiki and Effectopedia, which can be found within the AOP Knowl-
edge Base (a hub established by the OECD in collaboration with
the US Environmental Protection Agency (EPA), the European
Commission Joint Research Centre ( JRC) and the US Army Engi-
neer Research and Development Center (ERDC); https://aopkb.
org/). These platforms represent an evolution in the development
of AOPs that enable the organized collection and sharing of knowl-
edge through international crowd-sourcing, to facilitate the trans-
parent building of content within the AOPs currently included in
the OECD’s AOP Workplan. Final acceptance of the AOPs after this
development process will require a more formal procedure,
including independent critical review. In this way, AOPs will be de-
veloped and used in a transparent manner. Transparency in AOP
development is a critical issue, particularly when considering their
potential application for regulatory purposes. Such transparency
will also facilitate interoperability across different areas of human
toxicology and ecotoxicology, thereby facilitating widespread,
global applicability. The AOP framework further provides the op-
portunity to link different research programmes, particularly those
which focus on the avoidance of in vivo testing. Examples of these
include the EU SEURAT-1 initiative (a research programme funded
jointly by the European Commission and the cosmetics industry,
represented by Cosmetics Europe) to fill current gaps in scientific
knowledge and accelerate the development of non-animal test
methods in the complex area of repeated dose toxicity (www.seu-
rat-1.eu); and the US Tox21 programme (www.epa.gov/ncct/
Tox21), which pools resources from governmental organisations
(NIH-NCATS, NIH-NIEHS, EPA and FDA) to use robotics technology
to screen thousands of chemicals for potential toxicity, to use
screening data to predict the potential toxicity of chemicals, and
to develop a cost-effective approach for prioritizing the thousands
of chemicals that have not undergone toxicity testing.
There are four focus areas that will be key to the successful ex-
ploitation of the AOP framework in order for it to genuinely impact
on toxicology and safety assessment practice and, in turn, the 3Rs.
Exploitation of available information and data. There is generally
no need to generate new animal data to begin building AOPs, as
much of the mechanistic knowledge required is already available
within the peer-reviewed literature. AOPs offer an effective means
to distil out the essential features of this mechanistic information
and make the knowledge more accessible. However, a paradigm
shift may be needed to encourage scientists to share unpublished
data more openly. There is also a need to increase awareness
within the community about what data are already publicly avail-
able, e.g. the dissemination of information regarding accessible
databases.
Harmonization of approaches. The inherent variation in the ex-
panse and resolution of different AOPs presents a challenge, par-
ticularly with regards to the differing levels of description,
depending on the available knowledge and the nature of the path-
way itself. Therefore, in order for them to be successfully applied in
routine practice, a consensus agreement is necessary onwhat levelJ. Appl. Toxicol. 2015; 35: 971–975 Copyright © 2015 The Authors. J
published by John Wof information is required before an AOP is deemed useable, or al-
ternatively the widespread acceptance that the level of detail
needed will vary on a case-by-case basis and agreement reached
on what the minimum information requirements would be for
each scenario.
Above all, it is important that the data supplied are reliable and
that there is sufficient supporting evidence to prove linkage at
each step of the pathway. These are not new questions – for exam-
ple, see Meek et al. (2014) – and a consensus is emerging (OECD,
2013, 2014). Although only a certain minimal level of information
may be required to constitute an AOP, this should not discourage
the development of more comprehensive AOPs. Furthermore,
AOPs should be viewed as dynamic and evolving – an AOP is never
perfect or absolutely finalized – and it can be constantly updated
to ‘fill in the gaps’ and improve understanding. It is important that
all efforts in this area align with a harmonized and consistent
approach.
The development of an internationally agreed approach for the
development of AOPs, under the OECD framework, provides a
clear methodology for informing the Test Guidelines Programme
towards the identification and prioritisation of new in vitro test
methods that are candidates to become OECD Test Guidelines;
the OECD QSAR Toolbox Project for the identification of new
methods/profilers for grouping chemicals; and OECD Hazard
Assessment activities for the development of IATA, for defined
hazard endpoints. It is also more likely that regulatory acceptance
of non-animal (vertebrate) methods will be achieved if there has
been an agreement early-on around appropriate levels of informa-
tion required to build and apply an AOP, and if regulators are
involved in this process.
Fostering of collaborations. The focus on establishing the under-
lying biological mechanisms and key events in order to build AOPs
requires input across multiple scientific disciplines, providing a
communication tool and an opportunity to bring together tech-
nologies and understanding across the wider scientific commu-
nity, thus reaching out to new fields and creating collaboration
opportunities that were not available before. This could help to ca-
talyse the design of informative non-animal methods for toxicity
testing, by identifying novel applications for technologies such as
in silico, QSAR, high throughput screening and ‘omics approaches,
as well as to provide a platform for discussions among basic scien-
tists, regulators, risk assessors and risk managers and industry. In
addition, it is possible that the information gained from AOPs
could be utilized by mathematical and computational modellers
to produce more quantitative AOPs, where the key event forms
the basis of quantitative dose-responsemodels, and could provide
more predictive information than the dose-responses for apical
endpoints. The development and success of the framework will
depend on buy-in and acceptance from multiple-disciplines, in-
cluding input from regulators when deciding how this could be
used for safety assessment within a regulatory context.
Engaging regulators in the acceptance of mechanistic data and alter-
native methods. Regulatory acceptance is a major roadblock, not
only for AOPs, but in many cases for non-animal toxicity data if we
are to use these approaches in the wider setting and if we expect
to see real 3Rs benefits. There has been some inconsistency in the
use of mechanistic/AOP information within safety assessment
amongst regulators, e.g. the cancer risk assessment of TCDD (Popp
et al., 2006); the time is now right to engage regulators in these dis-
cussions, and to identify where and how the differences of opinion
come about. There are several questions relevant to the use ofournal of Applied Toxicology
iley & Sons Ltd.
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974AOPs in a regulatory context that must be to be answered, includ-
ing: What are the weight-of-evidence considerations necessary be-
fore an AOP can be accepted? Would reduced inter-species
extrapolation factors on the basis of an AOP be accepted? More-
over, would an AOP based solely on in vitro or computational data
ever be acceptable as a basis for chemical safety assessment?Towards the Use of AOPs in Practice
Now that the AOP framework is here, and there is subsequently
much investment in AOP development, we need to consider
how best to ensure that they will really be utilized and applied in
practice and that the efforts thus far do not prove futile.
First, the development of AOPs should take into account their
intended application. For use in a regulatory context, it is necessary
to maintain a focus on the regulatory goal of the activity and to
foster an appreciation that endpoints other than apical endpoints
could be used for safety assessment. This will require discussion
and agreement amongst relevant organisations worldwide. It is
also important that the bigger picture is not ignored. For example,
it is necessary that the conditions that propagate the AOP (i.e. cau-
sality) are defined, and that toxicokinetics and exposure/dose rela-
tionships are considered, as these could alter the extent to which
the normal biological process is perturbed, the consequent course
of events and the final adverse outcome. Efforts must be made
around understanding the quantitative linkages between down-
stream key events, as well as accounting for inter-individual vari-
ability, and variations in key event-dose relationships.
As previously mentioned, efforts are already underway to incor-
porate AOPs into the process of informing and/or directing IATAs.
Other ways in which AOPs could be applied for safety assessment
should also be considered; for example, there is potential to use
them to justify or contribute towards decisions that are made in
a regulatory setting, such as in the choice of appropriate uncer-
tainty factors or chemical-specific adjustment factors (CSAFs).
Further possible applications include their use in the identification
of appropriate dose metrics within safety assessment, as well as in
the grouping of chemicals for cumulative safety assessment, and
in category formation and read-across.
Finally, as previously alluded to, it is possible that less well-
defined AOPs would be adequate for de-prioritizing molecules
during the development process, through their use in screening
level assessments and prioritization decisions, for example the
use of potency for the MIE to rank chemicals. In this way, AOPs
could be used to improve the early-screens employed for go/no-
go decisions, and thus decrease the numbers of failures of
compounds at later stages by helping to prioritise chemicals taken
forward for more detailed assessment. There could also be the op-
tion to identify potential adversity from complex mixtures where
chemical analysis alone is insufficient. One impact of their use at
early development stages could be to cut down on numbers of
molecules going through to in vivo test stages, or in ecotoxicology
to help focus on invertebrate models, and could thus have further
benefits such as the saving of significant time and resource. If used
in this way, the data generated could be compared with those
from the traditional regulatory toxicity tests, to help towards
validation efforts, to build regulatory confidence, and to inform
applicability domains.
Efforts are now underway to enable the practical application of
the most well-defined AOP, that of skin sensitization initiated by
covalent binding of chemical to proteins (OECD, 2012). This is a
pertinent example of how the assimilation of knowledge aboutwileyonlinelibrary.com/journal/jat Copyright © 2015 The Authors.
published by John Wunderlying chemical and biological processes can be used to en-
able the distillation of the mechanisms into a number of key
events that are proven to result in an adverse health effect in
humans. The establishment of this AOP will allow for the exploita-
tion of the various in vitro methods that have been developed to
assess skin sensitization, and illustrates how collaborative efforts
by the scientific community through a coordinated framework
could lead to the incorporation of a mechanistic understanding
into an effective risk assessment process. The next stage currently
underway is the utilization of this AOP to drive development of an
IATA; the aim now will be to ensure that current framework can
streamline efforts to progress AOPs in other areas, to the point
where they can make a meaningful contribution to safety
assessment.
Conclusion
It is clear that the well-considered use of AOPs has the potential to
drive positive change in toxicology towards a reduced reliance on
predictionsmade using vertebrate animalmodels and on themea-
surement of apical toxicity endpoints per se. The concept itself, and
the widespread international uptake, is already stimulating the de-
velopment of novel tools and screening methods and driving real
innovation within human toxicology and ecotoxicology. However,
for the true gains and a genuine 3Rs impact to be realised, wemust
continue to make concerted efforts to collect, integrate and orga-
nise data from relevant sources, across scientific disciplines, to re-
alise the benefits of having a coherent framework. This will also
require regulatory input, to provide advice on how information
from AOPs can be used in decision making.
Even if AOPs in themselves do not come to fruition for use in a
regulatory setting, the current large-scale investment into their de-
velopment will undoubtedly accelerate the progress, understand-
ing and use of non-animal methods, and could go some way
towards convincing regulators to move away from relying for the
most part on the traditionally used animal tests. There is no doubt
that AOPs have a place in the prediction of chemical and drug tox-
icity; it is now time for the safety assessment community to decide
how and where their application can have the greatest scientific
and 3Rs benefits, and work together to enable this transition.
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